ERBB2 and neoplasm: In a study carried out on trastuzumab-resistant tumor models, Lorinc Nagy et al. labeled CAR-T cells with monomeric streptavidin molecules (mSA2) to identify HER-2 via binding to the biotin-linked trastuzumab.